pharmacotherapy of depression Flashcards
what are pathologies related to depression
Stroke
Chronic pain syndrome: Fibromyalgia, Low back pain / Chronic pelvic pain, Bone or disease related pain
Multiple sclerosis
Hypo / hyperthyroidism
Traumatic Brain Injury (TBI)
DSM-5 diagnostic criteria
At least one of the symptoms must be depressed mood or
loss of interest or pleasure in doing things
Recurrence
risk becomes lower over time as duration of remission increases
persistent mild symptoms during remission is a predictor of recurrence
function deteriorates during the episode and goes back to baseline upon remission
What is SIGE CAPS
Sleep (insomnia/hypersomnia
Interest decreased (anhedonia)
Guilt/worthlessness
Energy loss/fatigue
Concentration difficulties
Appetite change (increase or decrease)
Psychomotor agitation/retardation
Suicidal ideation
Self administered rating scales
Patient Health Questionnaire:(PHQ-9) Developed for the primary care setting
Mood Disorder Questionnaire (MDQ):Can be used to rule out bipolar disorder
What is the boxed warning risk for all antidepressant medications
Boxed warning for suicidality in ALL antidepressant medications (2004)
(for patients aged < 24 years of age)
what is the acute phase of depression treatment.
6-12 weeks or remission of symptoms
*Goal: induce remission
What is the continuation phase of depression treatment
4-9 additional months, recommended for all patients
Goal: prevent relapse
What is the maintenance phase of depression treatment
Patient-specific duration Often indefinite
treatment if ≥ 3 major depressive episodes
Goal: prevent recurrence Maintenance
What are SSRIs
Citalopram (Celexa)
Escitalopram (Lexapro)
Fluoxetine (Prozac)
Fluvoxamine (Luvox)
Paroxetine/Paroxetine CR (Paxil)
Sertraline (Zoloft)
What are Citalopram (Celexa) clinical pearls
Dose-dependent QTc prolongation
Substrate of 2C19 and 3A4
What are Fluoxetine (Prozac) clinical pearls
Long half-life (96-144 hours)
Activating potential
2D6 inhibitor, 3A4 inhibitor (norfluoxetine
Fluvoxamine (Luvox) clinical pearls
inhibitor 1A2, 2C19
Paroxetine/Paroxetine CR (Paxil) clinical pearls
MUST taper due to anticholinergic effects
Weight gain, sedation
Septal wall defect risk to the fetus
Inhibitor 2D6, 2B6
Sertraline (Zoloft) clinical pearls
More GI upset than other antidepressant
What drugs are SNRIs
Desvenlafaxine (Pristiq)
Duloxetine (Cymbalta)
Levomilnacipran (Fetzima)
Milnacipran (Savella)
Venlafaxine (Effexor)
What are the adverse effects of SSRIs
Weight gain (paroxetine)
Weight loss (fluoxetine)
Increased bleeding risk (platelet inhibition)
Hyponatremia (especially in elderly)
Sexual dysfunction
Desvenlafaxine (Pristiq) clinical pearls
Active metabolite of venlafaxine
Dose-limiting side effect: nausea
No major CYP interactions
Duloxetine (Cymbalta) clinical pearls
nausea
FDA warning for hepatotoxicity
Inhibitor 2D6
Levomilnacipran (Fetzima) clinical pearls
MUST adjust in renal impairment or strong 3A4 inhibitors
Substrate 3A4
Venlafaxine (Effexor) clinical pearls
Must be >150 mg/day to have NE effects
2D6 inhibitor at higher doses
SNRI adverse effects
blood pressure elevation and nausea useful in pain syndrome musculoskeletal pain fibromyalgia and neuropathic pain
duloxetine obtain LFTs at baseline and when symptomatic or every 6 months
what are TCAs
Blockade of reuptake transporter (DAT, SERT, NET) -> inhibits the reuptake of serotonin, norepinephrine, and dopamine
Amitriptyline (Elavil) Tertiary amine
TCAs – Adverse Effects/Key Points
CNS: sedation, reduced seizure threshold, confusion
Anticholinergic: blurred vision, urinary retention, constipation
Cardiovascular: orthostatic hypotension, tachycardia
Other: weight gain, sexual dysfunction
Side effects often limit higher doses:
Narrow therapeutic index: Fatal in overdose as low as 1000 mg (~4-10 tablets) due to cardiac arrhythmias or
seizures